The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I dose-escalation trial of intraperitoneal oxaliplatin with systemic capecitabine and bevacizumab following cytoreduction in patients with peritoneal carcinomatosis from appendiceal or colorectal cancer.
 
Aabha Oza
No Relationships to Disclose
Oxaliplatin (OXA), Irinotecan (CPT11), and 4-Day Continuous Infusion 5-Fluorouracil (CIVFU) Every Three Weeks (Q3W): A Phase I Study in Advanced Gastrointestinal Tumors.
 
Patrick Grierson
No Relationships to Disclose
 
Sean Glasgow
No Relationships to Disclose
 
Katrina Pedersen
Speakers' Bureau - Clinical Care Options
 
Stephen Barman
No Relationships to Disclose
 
Thomas Westbrook
No Relationships to Disclose
 
Matthew G Mutch
No Relationships to Disclose
 
Andrea Wang-Gillam
Consulting or Advisory Role - Merrimack; Newlink Genetics; pfizer
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); CTI (Inst); EMD Serono (Inst); Halozyme (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst); OncoMed (Inst); pfizer (Inst); Plexxikon (Inst); Precision Therapeutics (Inst); Verastem (Inst)
 
Rama Suresh
No Relationships to Disclose
 
Ashley Morton
Speakers' Bureau - Guardant Health
Other Relationship - Guardant Health
 
Samantha Marquez
No Relationships to Disclose
 
James W Fleshman
No Relationships to Disclose
 
Benjamin R. Tan
Consulting or Advisory Role - Roche/Genentech
Research Funding - Bayer; Boehringer Ingelheim; Eisai; Exelixis; Lilly; Merck Serono; Pfizer; Roche/Genentech; Sillajen; tyrogenex